The finalists of the St. Petersburg University startup competition have developed a technology that can minimize surgical intervention in the treatment of tumor diseases. It is based on the principle of gene therapy as an approach to the elimination of uterine fibroids.
According to the press service of the university, the most common way to treat a benign tumor of a female muscular organ is surgical removal. The authors of the GenomeX project have found a treatment method that will reduce the risk of violations and maintain the effectiveness of the impact. In the laboratory, based on peptide carriers, they developed a non-viral nucleic acid delivery system.
Team captain Alexander Baichikov told what the treatment would be like for the patient. “It’s just a poke. A person comes to the clinic, which is already treating uterine fibroids, but surgically, and instead of surgical removal, makes an injection into the uterus, ideally intravenously. And that’s all,” explained Alexander Baichikov.
In addition, the technology of peptide carriers can be applied not only to fibroids, but also to other organs and tissues.
Work has already been carried out on primary fibroid cells obtained directly from patients, and separately on myoma nodes taken after tumor removal.
Source: Rosbalt
Mario Twitchell is an accomplished author and journalist, known for his insightful and thought-provoking writing on a wide range of topics including general and opinion. He currently works as a writer at 247 news agency, where he has established himself as a respected voice in the industry.
